We are live on !
Find out more
Deerfield Management Portfolio holdings
AUM
$9.6B
Turnover
24.47%
1-Year Est. Return
113.36%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+113.36%
3 Year Est. Return
+277.48%
5 Year Est. Return
+350.78%
10 Year Est. Return
+2,290.11%
AUM
$9.6B
AUM Growth
+$1.11B
(+13%)
Cap. Flow
-$1.32B
Cap. Flow % of AUM
Cap. Flow %
-13.72%
Top 10 Holdings %
Top 10 Hldgs %
53.17%
Holding
94
New
11
Increased
13
Reduced
11
Closed
12
Avg Time Held
1.9
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Genmab
GMAB
|
+$117M |
| 2 |
Mineralys Therapeutics
MLYS
|
+$109M |
| 3 |
Boston Scientific
BSX
|
+$71.4M |
| 4 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$52M |
| 5 |
IDEAYA Biosciences
IDYA
|
+$36.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cogent Biosciences
COGT
|
+$141M |
| 2 |
Catalyst Pharmaceutical
CPRX
|
+$97.6M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$80.4M |
| 4 |
Day One Biopharmaceuticals
DAWN
|
+$79.8M |
| 5 |
Enhabit
EHAB
|
+$66.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.76% |
| 2 | Miscellaneous | 16.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Alnylam Pharmaceuticals
ALNY
$30B
| $20.5M | 0.21% |
67,935
| – | – |
2024 Q2
8 quarters
|
|
52
Bright Minds Biosciences
DRUG
$518M
| $19.9M | 0.21% |
283,000
| – | – |
2026 Q1
1 quarter
|
|
53
Odyssey Therapeutics
ODTX
$942M
| $19.6M | 0.2% |
+1,046,139
| New | +$18.3M |
2026 Q2
0 quarters
|
|
54
Starling Oncology
STLN
$684M
| $18.2M | 0.19% |
3,360,052
| – | – |
2020 Q4
22 quarters
|
|
55
Kyverna Therapeutics
KYTX
$333M
| $17.8M | 0.19% |
2,000,000
| – | – |
2025 Q4
2 quarters
|
|
56
Alamar Biosciences
ALMR
$2.13B
| $16.3M | 0.17% |
+600,000
| New | +$13.6M |
2026 Q2
0 quarters
|
|
57
Chemed
CHE
$6.7B
| $14M | 0.15% |
+30,000
| New | +$12.6M |
2026 Q2
0 quarters
|
|
58
SpyGlass Pharma
SGP
$953M
| $12.2M | 0.13% |
550,000
| – | – |
2026 Q1
1 quarter
|
|
59
Adagene
ADAG
$162M
| $11.2M | 0.12% |
+2,666,666
| New | +$10M |
2026 Q2
0 quarters
|
|
60
Hemab Therapeutics
COAG
$1.61B
| $10.1M | 0.11% |
+275,000
| New | +$7.59M |
2026 Q2
0 quarters
|
|
61
Mobia Medical
MOBI
$347M
| $8.99M | 0.09% |
+670,752
| New | +$8.69M |
2026 Q2
0 quarters
|
|
62
Embecta
EMBC
$380M
| $8.26M | 0.09% |
2,534,961
| – | – |
2023 Q4
10 quarters
|
|
63
Veracyte
VCYT
$3.85B
| $5.93M | 0.06% |
101,000
-625,000
| -86% | -$26.2M |
2025 Q2
4 quarters
|
|
64
Annexon
ANNX
$711M
| $3.33M | 0.03% |
583,913
| – | – |
2020 Q3
23 quarters
|
|
65
Alector
ALEC
$204M
| $2.12M | 0.02% |
1,055,192
| – | – |
2019 Q1
29 quarters
|
|
66
NewAmsterdam Pharma Warrant
NAMSW
$42.6M
| $1.98M | 0.02% |
92,787
| – | – |
2022 Q4
14 quarters
|
|
67
Edwards Lifesciences
EW
$51.3B
| $1.24M | 0.01% |
13,702
| – | – |
2025 Q3
3 quarters
|
|
68
Mirum Pharmaceuticals
MIRM
$5.22B
| $706K | 0.01% |
+6,027
| New | +$605K |
2026 Q2
0 quarters
|
|
69
Humana
HUM
$50.7B
| $364K | ﹤0.01% |
917
| – | – |
2024 Q4
6 quarters
|
|
|
70
Starling Oncology Warrant
STLNW
| $51K | ﹤0.01% |
1,250,000
| – | – |
2021 Q1
21 quarters
|
|
71
PMV Pharmaceuticals
PMVP
$67.9M
| $11.8K | ﹤0.01% |
8,790
| – | – |
2025 Q2
4 quarters
|
|
72
DELISTED
Surrozen Inc Warrant
SRZNW
| $2.75K | ﹤0.01% |
166,666
| – | – |
2021 Q3
19 quarters
|
|
73
Cullinan Oncology
CGEM
$925M
| – | – |
-386,169
| Closed | -$5.49M | – |
|
74
Compass Therapeutics
CMPX
$137M
| – | – |
-3,606,000
| Closed | -$19.1M | – |
|
|
75
DELISTED
Catalyst Pharmaceutical
CPRX
| – | – |
-3,943,600
| Closed | -$97.6M | – |
|
Similar funds
SC
Deerfield Management's Q2 2026 Portfolio in Review
As of Q2 2026, Deerfield Management held 94 positions worth $9.6B, up 13% from $8.48B the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Deerfield Management withdrew a net $1.32B in Q2 2026, closing 12 positions and reducing 11 holdings. Its most notable exit was Catalyst Pharmaceutical, an estimated $97.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 85% a quarter earlier, followed by Miscellaneous.
Against the trend, Deerfield Management opened a new position in Mineralys Therapeutics worth $107M.
- Deerfield Management's largest Q2 2026 buy was Mineralys Therapeutics: 3,958,000 shares worth $107M.
- Deerfield Management added most to Genmab in Q2 2026, an estimated $117M increase.
- Deerfield Management's biggest Q2 2026 reduction was Cogent Biosciences, cutting an estimated $141M.
- Deerfield Management fully exited Catalyst Pharmaceutical in Q2 2026, selling an estimated $97.6M.
- Deerfield Management's ten largest holdings make up 53% of its $9.6B portfolio in Q2 2026.
- Deerfield Management opened 11 new positions and closed 12 in Q2 2026.
- Deerfield Management's portfolio value rose 13% quarter-over-quarter to $9.6B.
Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.